CNBC-TV18 accesses Form 483 issued to Lupin’s Nagpur plant

#USFDA issues 2 #observations for #Lupin’s Nagpur plant, says Lab records do not include a complete record of all data obtained during testing

Alert: US FDA inspected Lupin’s Nagpur plant from July 3-11 https://t.co/qDd8weLFPB https://t.co/DH4QfhPenK

#JustIn | #Lupin incorporates unit Lupin Atharv ability for neuro-rehabilitation business https://t.co/DgmxoVTNmc

#JustIn | #Lupin arm launches Luforbec in Germany used for chronic obstructive pulmonary disease (COPD) https://t.co/rBQxFOA4SZ

#JustIn | #Lupin collaborates with American College of Cardiology to deliver in-home cardiovascular care to accelerate application & adoption of DTX in cardiology in India https://t.co/J2PV2eiSJ2

#NATCO files generic Erdafitinib Tablets in USA

#Embassy Office Parks REIT announces Q1FY24 results

#Sobhagya Mercantile Ltd to set up integrated steel plant

#MSR India Ltd sells land for debt reduction

#Lupin receives approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD

#REC Ltd declares interim dividend of Rs. 3

#Aegis Logistics Ltd declares interim dividend of Rs. 2.50

#TCS Positioned as a Market Leader in Data Modernization Services by HFS Research

#Power Finance Corporation Limited NCDs closed early, garners Rs 2922 crore

#Suraj Estate Developers refiles DRHP for Rs 400 crore IPO

#Lemon Tree Hotels signs a new property in Zirakpur, Punjab

#Mahindra and Mahindra Ltd acquires stake in RBL Bank Limited

#Healthcare Triangle Ransomware Protection and Prevention Initiative Draws Initial Support from Multiple Health System Clients

#Marico makes strategic investment in clean, plant-based nutrition brand 'Plix'

#Som Distilleries and Breweries Ltd captures 46% market share in Madhya Pradesh

#Jio Financial Services and BlackRock agree to form JV to enter India's Asset Management Industry

#Lupin announces resolution of US FDA warning letter for Goa and Pithampur facilities

Satisfactory evolution of corrective action taken by the company in response to warning letter issued on November 6, 2017, says co

#Lupin announces voluntary recall of two lots of the pregnancy prevention drug Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets 3mg/0.03mg/0.451mg and levomefolate calcium tablets 0.451mg) in the US https://t.co/SHUJjFvs3y

#JustIn | #Lupin gets US FDA approval for Turqoz used in treatment of bacterial & parasitic infections https://t.co/uLcBwJLoIu

#JustIn | #Lupin Digital Health launches Lyfe digital heart failure Clinic in India

#Lupin arm receives US FDA ANDA approval for Fluocinolone Acetonide Body Oil which used to treat Eczema, a skin condition https://t.co/Xtwz8KLWul

#JustIn | #Lupin gets US FDA ANDA nod for Bromfenac Ophthalmic Solution used for pain or swelling of eye following cataract surgery https://t.co/Rnaw7HV0Jy

#JustIn | #Lupin acquires Ondero & Ondero - Met brands from Boehringer Ingelheim for ₹235 crore https://t.co/vngy0zWJW5 https://t.co/kbeR9A0ktL

#JustIN | US FDA issues form 483 with zero observations for #Lupin’s injectable unit in Nagpur, this marks the closure of inspection at the unit

Injectable Unit In Nagpur was inspected by US FDA from June 10 -13, 2024

#JustIn | EU Court dismisses Lupin’s final appeal against EU commission order for fine of €40 m

#Lupin to pay €40 m fine & interest thereon to EU commission for Perindopril Case

#JustIn | #Lupin enters into patent agmt with Takeda Pharma to commercialise Vonoprazan Tablets in Indian market

#JustIn | #Lupin: US FDA issues 3 observations to co’s Pithampur facility, was inspected from September 16 to September 27

#Lupin signs distribution agreement with #SCOPE to commercialise Optase range of products in #Mexico

#JustIn | #Lupin: US FDA issues 5 observations at company’s Pune facility, the inspection was carried out from September 25, 2024 to October 4, 2024

#JustIn | #Lupin Launches First Generic Of Pred Forte (Prednisolone Acetate) In The US

#Lupin raises FY25 core margin and EBITDA margin guidance

--Core margin now seen in the range of 23-25% Vs previous guidance of 23-24%

--EBITDA margin now seen in the range of 22-23% Vs previous guidance of 20.5-21%